Toggle Health Problems and D

Kidney Dialysis clinics reluctant to add vitamin D treatment as they are not reimbursed – Oct 2012

And – treating with vitamin D would decrease their number of patients thus and their income

A cost effective complement to managing the vitamin D deficient and anemic dialysis patient in the bundled world.

Nephrol News Issues. 2012 Jul;26(8):22-4, 26.
Larkin J, Bea L, Sharma A.
Pacific Renal Research Institute, Caldwell, Idaho, USA.

Vitamin D deficiency is a common health complication in patients with chronic kidney disease and can be treated with an abundance of classical and advanced pharmaceutics. However, the impact of bundling in dialysis clinics limits the use of the most optimal therapeutics and desired efficacy targets in end-stage renal disease patients.

To address this issue, we investigated the benefits of adding a cost-effective antioxidant and vitamin D nutraceutical (MV-ONE, Nephrian Inc.) to patient regiments. This nutraceutical was used in an attempt to replete vitamin D levels and decrease inflammation that dialysis patients experience. Additionally, we investigated the potential of this therapy to reduce the need for erythropoietin-stimulating agents.

Results indicate MV-ONE caused:

  • (1) increases in 25-OH vitamin D (p = 0.0058),
  • (2) decreases in ESA dose (p = 0.0475), and
  • (3) no change in C-reactive protein (p = 0.3290).

Overall, this suggests the addition of MV-ONE does benefit the vitamin D deficiency and anemia observed in ESRD patients.

See also VitaminDWiki

from Vitamin D and Chronic Kidney Disease - June 2010  in Kidney gallery

See also web

Kidney Dialysis clinics reluctant to add vitamin D treatment as they are not reimbursed – Oct 2012        
4422 visitors, last modified 24 Sep, 2022,
Printer Friendly PDF this page! Follow this page for updates
See any problem with this page? Report it (WORKS NOV 2021)